Free Trial

CRISPR Therapeutics (CRSP) Stock Forecast & Price Target

CRISPR Therapeutics logo
$46.39
-1.54 (-3.21%)
(As of 10/31/2024 ET)

CRISPR Therapeutics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
2
Hold
8
Buy
9

Based on 19 Wall Street analysts who have issued ratings for CRISPR Therapeutics in the last 12 months, the stock has a consensus rating of "Hold." Out of the 19 analysts, 2 have given a sell rating, 8 have given a hold rating, and 9 have given a buy rating for CRSP.

Consensus Price Target

$75.19
62.08% Upside
According to the 19 analysts' twelve-month price targets for CRISPR Therapeutics, the average price target is $75.19. The highest price target for CRSP is $105.00, while the lowest price target for CRSP is $30.00. The average price target represents a forecasted upside of 62.08% from the current price of $46.39.
Get the Latest News and Ratings for CRSP and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for CRISPR Therapeutics and its competitors.

Sign Up

CRSP Analyst Ratings Over Time

TypeCurrent Forecast
11/1/23 to 10/31/24
1 Month Ago
10/2/23 to 10/1/24
3 Months Ago
8/3/23 to 8/2/24
1 Year Ago
11/1/22 to 11/1/23
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
9 Buy rating(s)
9 Buy rating(s)
9 Buy rating(s)
10 Buy rating(s)
Hold
8 Hold rating(s)
8 Hold rating(s)
8 Hold rating(s)
5 Hold rating(s)
Sell
2 Sell rating(s)
2 Sell rating(s)
2 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$75.19$75.63$76.67$71.56
Forecasted Upside62.08% Upside65.92% Upside50.00% Upside63.56% Upside
Consensus Rating
Hold
Hold
Hold
Moderate Buy

CRSP Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

CRSP Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

CRISPR Therapeutics Stock vs. The Competition

TypeCRISPR TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
2.37
2.79
2.50
Consensus RatingHoldModerate BuyHold
Predicted Upside56.87% Upside15,724.54% Upside9.23% Upside
News Sentiment Rating
Positive News

See Recent CRSP News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
10/4/2024Royal Bank of Canada
4 of 5 stars
 Lower TargetSector Perform ➝ Sector Perform$60.00 ➝ $53.00+17.52%
8/12/2024Truist Financial
2 of 5 stars
 Lower TargetBuy ➝ Buy$120.00 ➝ $100.00+110.84%
8/8/2024Cantor Fitzgerald
3 of 5 stars
 Reiterated RatingNeutral
8/6/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetEqual Weight ➝ Equal Weight$67.00 ➝ $59.00+17.60%
8/6/2024Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$88.00 ➝ $84.00+69.15%
8/6/2024Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$112.00 ➝ $94.00+89.29%
8/6/2024Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetHold ➝ Hold$60.00 ➝ $59.00+18.81%
8/2/2024Rodman & Renshaw
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$90.00+64.08%
6/28/2024Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
D. Chattopadhyay
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral
6/17/2024Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOverweight ➝ Overweight$105.00 ➝ $105.00+71.65%
5/23/2024Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$89.00 ➝ $84.00+50.27%
5/10/2024Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform ➝ Outperform$102.00 ➝ $95.00+85.19%
5/9/2024JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingMarket Outperform ➝ Market Outperform$86.00+61.65%
5/9/2024Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetEqual Weight ➝ Equal Weight$70.00 ➝ $65.00+24.12%
5/9/2024Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral ➝ Neutral$46.00 ➝ $52.00-2.42%
3/6/2024Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$82.00 ➝ $99.00+22.24%
2/26/2024Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetUnderweight ➝ Underweight$46.00 ➝ $48.00-43.64%
2/15/2024Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoveragePeer Perform
12/11/2023TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeMarket Perform ➝ Underperform$30.00-53.52%
8/8/2023Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral ➝ Neutral$62.00 ➝ $63.00+30.33%
5/30/2023William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
S. Corwin
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$75.00+15.99%
5/9/2023VNET Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingReiterates
4/17/2023EF Hutton Acquisition Co. I
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy$75.00+38.63%
3/21/2023Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageMarket Perform$44.00-1.03%
3/17/2023Bryan, Garnier & Co
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$70.00+54.22%
11/7/2022Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform$75.00 ➝ $76.00+48.50%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 06:54 PM ET.


CRSP Forecast - Frequently Asked Questions

According to the research reports of 19 Wall Street equities research analysts, the average twelve-month stock price forecast for CRISPR Therapeutics is $75.19, with a high forecast of $105.00 and a low forecast of $30.00.

19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CRISPR Therapeutics in the last twelve months. There are currently 2 sell ratings, 8 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" CRSP shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CRSP, but not buy additional shares or sell existing shares.

According to analysts, CRISPR Therapeutics's stock has a predicted upside of 62.08% based on their 12-month stock forecasts.

CRISPR Therapeutics has been rated by research analysts at Barclays, Cantor Fitzgerald, Chardan Capital, Needham & Company LLC, Rodman & Renshaw, Royal Bank of Canada, Stifel Nicolaus, and Truist Financial in the past 90 days.

Analysts like CRISPR Therapeutics less than other "medical" companies. The consensus rating for CRISPR Therapeutics is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how CRSP compares to other companies.


This page (NASDAQ:CRSP) was last updated on 10/31/2024 by MarketBeat.com Staff
From Our Partners